Welcome to our dedicated page for Longeveron news (Ticker: LGVNR), a resource for investors and traders seeking the latest updates and insights on Longeveron stock.
Longeveron Inc. (LGVNR) generates news as a clinical stage biotechnology company developing regenerative medicines based on its lead mesenchymal stem cell therapy, laromestrocel (Lomecel-B). Company announcements frequently focus on progress in clinical trials, new scientific data, intellectual property developments, and participation in major medical and industry forums.
Recent news highlights include updates on the pivotal Phase 2b ELPIS II trial evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric congenital heart defect. Longeveron also reports on its Alzheimer’s disease program, including Phase 2 data from the CLEAR MIND trial showing MRI biomarker evidence of reduced neuroinflammation and associations with preserved brain volume and clinical outcomes in mild Alzheimer’s disease.
Investors and observers can also see coverage of patents granted in the United States and Canada for methods of using Longeveron’s proprietary mesenchymal stem cells to treat aging-related frailty with inflammaging, non-ischemic dilated cardiomyopathy, and female sexual dysfunction. Additional news items describe FDA regulatory milestones, such as designations for laromestrocel in HLHS and Alzheimer’s disease, and acceptance of an IND for Pediatric Dilated Cardiomyopathy.
This page aggregates company press releases and third-party coverage related to Longeveron’s clinical programs, scientific presentations at conferences like CTAD and CVCT, and corporate updates. Users interested in LGVNR stock can review these updates to understand how Longeveron’s stem cell therapy platform is being evaluated across rare pediatric and aging-related conditions.
Longeveron reported its full-year 2024 financial results, highlighting a 237% year-over-year increase in total revenue to $2.4 million. The company's pivotal Phase 2b clinical trial (ELPIS II) for Lomecel-B™ in treating Hypoplastic Left Heart Syndrome has achieved over 90% enrollment, with completion expected in Q2 2025.
Key financial metrics include a reduced net loss of $16.0 million (down 25% from 2023), with cash and equivalents of $19.2 million as of December 31, 2024. The company anticipates its current funds will support operations into Q4 2025.
Notable developments include WHO's approval of 'laromestrocel' as Lomecel-B's non-proprietary name and plans for a potential Biological License Application (BLA) submission in 2026. The company expects an FDA meeting in late Q1 2025 to discuss development paths for Lomecel-B in mild Alzheimer's disease.
Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company, has announced it will release its full-year 2024 financial results on Friday, February 28, 2025, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. ET the same day to discuss results and provide a business update. An archived replay will be available on the company's website following the conference.
Longeveron (NASDAQ: LGVN) announced that its cellular therapy Lomecel-B™ has received the International Non-proprietary Name (INN) 'laromestrocel' from the World Health Organization. Lomecel-B™ is being evaluated for Alzheimer's disease and hypoplastic left heart syndrome (HLHS), a rare pediatric disease.
The therapy has received multiple FDA designations, including Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designation for mild Alzheimer's disease, as well as Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation for HLHS treatment. The company has reported positive Phase 2a data in mild Alzheimer's disease and is nearing completion of enrollment for its Phase 2b HLHS clinical trial.
Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company, has announced its participation in the upcoming Emerging Growth Virtual Conference. The company, which focuses on developing cellular therapies for life-threatening and chronic aging-related conditions, will present on February 19, 2025, from 3:10 to 3:20 p.m. ET.
Interested parties can access the presentation through the 'Events and Presentations' section of Longeveron's website. The webcast replay will remain available for 180 days after the conference. Questions can be submitted in advance to Questions@EmergingGrowth.com or asked during the live event.
Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company, has announced its upcoming participation at Biotech Showcase 2025. CEO Wa'el Hashad will deliver a corporate presentation on Tuesday, January 14, 2025, from 4:00 to 4:30 p.m. PT.
The company, which focuses on developing cellular therapies for life-threatening and chronic aging-related conditions, will make the presentation available via webcast through the 'Events and Presentations' section of their website. A replay will be accessible on Longeveron's website after the conference concludes.
Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company, has announced its participation in the Emerging Growth Virtual Conference scheduled for December 4-5, 2024. The company will present on December 5, 2024, from 12:00 to 12:30 p.m. ET.
The presentation will be accessible through the company's website under the 'Events and Presentations' section, with the webcast replay available for 180 days following the conference. Participants can submit questions in advance to Questions@EmergingGrowth.com or during the event.
Longeveron reported Q3 2024 financial results and business updates. The company's Phase 2b ELPIS II trial for Lomecel-B™ in HLHS has reached 80% enrollment, with FDA confirming it as pivotal for BLA submission. Total revenue increased 177% to $1.8M in the first nine months of 2024. Operating expenses decreased 14% year-over-year. The company maintains $22.8M in cash, expected to fund operations through Q4 2025. Notable developments include positive Phase 2a CLEAR MIND trial data in Alzheimer's disease and successful Type C FDA meeting confirming ELPIS II's pivotal status.
Longeveron (NASDAQ: LGVN) has appointed Devin Blass as Chief Technology Officer and Senior Vice President of Chemistry, Manufacturing, and Controls, effective December 2, 2024. Blass brings over 15 years of experience in advanced therapies development and manufacturing. His appointment comes at a important time as the company prepares for a potential Biological License Application submission for HLHS, pending positive results from the ongoing ELPIS II trial. Prior to joining Longeveron, Blass served at the New York Blood Center as SVP of Comprehensive Cell Solutions and held leadership positions at Talaris Therapeutics, Bellicum Pharmaceuticals, and Mesoblast.
Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company, has scheduled its third quarter 2024 financial results announcement for November 12, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. ET the same day to discuss results and provide a business update. The conference call will be accessible via phone (1.877.407.0789) with Conference ID 13749428, and a webcast replay will be available on the company's website.
Longeveron presented data on Lomecel-B, their cellular therapy for mild Alzheimer's disease (AD), at the CTAD24 conference. The presentation highlighted that Lomecel-B's ability to inhibit MMP14 correlates with improved clinical outcomes in mild AD patients. Research from the Phase 2a CLEAR MIND trial showed that patients receiving Lomecel-B lots with higher MMP14 inhibitory activity demonstrated enhanced responses versus placebo on various measures, including cognitive function, quality of life, and brain volume. The findings suggest that MMP14 inhibition may protect TIE2 receptor integrity and contribute to the immunomodulatory and pro-vascular effects of Lomecel-B in mild AD treatment.